| Previous Close | 0.9989 |
| Open | 0.9989 |
| Bid | 0.5000 x 1000 |
| Ask | 1.2500 x 11000 |
| Day's Range | 0.9600 - 1.0400 |
| 52 Week Range | 0.7800 - 5.5900 |
| Volume | 110,056 |
| Avg. Volume | 436,414 |
| Market Cap | 13.78M |
| Beta | N/A |
| PE Ratio (TTM) | -0.43 |
| EPS (TTM) | -2.28 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- Zacks•12 days ago
Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options
Investors need to pay close attention to Aeterna Zentaris (AEZS) stock based on the movements in the options market lately.
- Business Wire•19 days ago
Aeterna Zentaris to Present at 2017 Marcum MicroCap Conference
Aeterna Zentaris Inc. today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the 2017 Marcum MicroCap Conference on Friday, June 16, 2017 at 9:30 a.m.
Capital Cube•26 days agoÆterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
Categories: Yahoo FinanceGet free summary analysis Æterna Zentaris, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Æterna Zentaris, Inc. – Spectrum Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Bristol-Myers Squibb Company, Halozyme Therapeutics, Inc. and Novartis AG Sponsored ADR (SPPI-US, KERX-US, BMY-US, HALO-US and NVS-US) that ... Read more (Read more...)